financetom
Business
financetom
/
Business
/
Engineering consulting firm Exponent Q3 net income rises 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Engineering consulting firm Exponent Q3 net income rises 
Oct 30, 2025 2:21 PM

Overview

* Exponent fiscal Q3 revenue grows 8% yr/yr, driven by diversified portfolio strength

* Net income for Q3 rises to $28 mln, reflecting strong operational performance

* Company increases stock repurchase program by $100 mln, indicating confidence in growth

Outlook

* Exponent maintains revenue guidance and raises margin guidance for full year 2025

* Company expects Q4 2025 revenue growth in low to mid-single digits

* Exponent anticipates full-year 2025 EBITDA margin of 27.4% to 27.65%

Result Drivers

* DISPUTE-RELATED WORK - Increasing demand for dispute-related work drove robust growth in energy, transportation, life sciences, and construction sectors

* PROACTIVE ENGAGEMENTS - Growth led by risk management and asset integrity projects in utilities and regulatory consulting in chemicals

* AI INTEGRATION - AI integration into safety-critical systems helps clients navigate risk and innovate responsibly

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.55

Q3 Net $28 mln

Income

Q3 $38.80

EBITDA mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the business support services peer group is "buy."

* Wall Street's median 12-month price target for Exponent Inc ( EXPO ) is $88.00, about 25.7% above its October 29 closing price of $65.41

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
Apr 17, 2024
05:45 PM EDT, 04/17/2024 (MT Newswires) -- NRx Pharmaceuticals ( NRXP ) late Wednesday disclosed plans for an upcoming public offering of its stock, subject to market and other conditions. Terms of the proposed sale, including the number of the shares to be offered and their price will become at a later date. The drugmaker expects to use any proceeds...
ImmunityBio Files Mixed Shelf
ImmunityBio Files Mixed Shelf
Apr 17, 2024
05:48 PM EDT, 04/17/2024 (MT Newswires) -- ImmunityBio ( IBRX ) filed an automatic shelf registration statement Wednesday for the potential sale of securities from time to time. The filing covers its common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units. ImmunityBio ( IBRX ) said it plans to use proceeds for advancing regulatory...
Cadence Design Introduces New Emulation, Prototyping Systems
Cadence Design Introduces New Emulation, Prototyping Systems
Apr 17, 2024
05:49 PM EDT, 04/17/2024 (MT Newswires) -- Cadence Design Systems ( CDNS ) said late Wednesday its new Palladium Z3 emulation and Protium X3 FPGA prototyping systems will allow rapid development of advanced chips for generative artificial intelligence, mobile, automotive, hyperscale and large language model applications. The systems offer increased capacity, and scale from job sizes of 16 million gates...
AdaptHealth Names Suzanne Foster as CEO
AdaptHealth Names Suzanne Foster as CEO
Apr 17, 2024
05:50 PM EDT, 04/17/2024 (MT Newswires) -- AdaptHealth ( AHCO ) said Wednesday it appointed Suzanne Foster as chief executive officer, effective May 20. She takes over from Richard Barasch, the chairman of the board who also served as interim CEO. Foster previously was president of Danaher's ( DHR ) Beckman Coulter Life Sciences, a global provider of biomedical technologies...
Copyright 2023-2026 - www.financetom.com All Rights Reserved